BOLT BIOTHERAPEUTICS

Bolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022

08 мар 2022 15:30:00 Источник Nasdaq GlobeNewswire

Bolt Biotherapeutics to Participate in Upcoming February Conferences

02 фев 2022 07:00:01 Источник Nasdaq GlobeNewswire

Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors

06 янв 2022 07:00:02 Источник Nasdaq GlobeNewswire

Bolt Biotherapeutics Appoints Nicole Onetto, M.D., to Board of Directors

16 дек 2021 07:00:02 Источник Nasdaq GlobeNewswire

Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021

06 дек 2021 05:00:00 Источник Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021

02 дек 2021 05:00:00 Источник Nasdaq GlobeNewswire

Bolt Biotherapeutics Announces Changes to its Board of Directors

19 ноя 2021 07:00:00 Источник Nasdaq GlobeNewswire

Bolt Biotherapeutics Presents New Preclinical Data on Three Pipeline Programs at Society for Immunotherapy of Cancer (SITC) Annual Meeting

12 ноя 2021 06:00:02 Источник Nasdaq GlobeNewswire

Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights

09 ноя 2021 03:05:00 Источник Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present at Stifel 2021 Virtual Healthcare Conference

08 ноя 2021 07:00:01 Источник Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present Updates on Three Pipeline Programs at the 2021 Society for Immunotherapy of Cancer Annual Meeting (SITC)

01 окт 2021 07:00:01 Источник Nasdaq GlobeNewswire

Bolt Biotherapeutics to Participate in Upcoming September Investor Conferences

02 сен 2021 07:00:02 Источник Nasdaq GlobeNewswire

Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs

26 авг 2021 15:05:00 Источник Nasdaq GlobeNewswire

Bolt Biotherapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights

12 авг 2021 15:05:04 Источник Nasdaq GlobeNewswire

Bolt Biotherapeutics Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001 at ASCO 2021

04 июн 2021 08:00:00 Источник Nasdaq GlobeNewswire

Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration

02 июн 2021 07:00:02 Источник Nasdaq GlobeNewswire

Bolt Biotherapeutics Reports First Quarter 2021 Financial Results and Provides Business Highlights

13 май 2021 15:05:00 Источник Nasdaq GlobeNewswire

Bolt Biotherapeutics Announces AACR 2021 Presentation of Boltbody™ Platform Mechanism of Action and Clinical Properties of Lead ISAC, BDC-1001

10 апр 2021 07:30:00 Источник Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

08 апр 2021 06:00:00 Источник Nasdaq GlobeNewswire

Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

31 мар 2021 15:05:00 Источник Nasdaq GlobeNewswire